50
Participants
Start Date
December 31, 2004
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
SGN-40 (anti-huCD40 mAb)
1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
Cornell University, New York
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
University of Texas MD Anderson Cancer Center, Houston
Stanford University, Stanford
Collaborators (1)
Genentech, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY